HUE046631T2 - VEGFR-2 targetáló DNS vakcina kombinációs terápiára - Google Patents

VEGFR-2 targetáló DNS vakcina kombinációs terápiára

Info

Publication number
HUE046631T2
HUE046631T2 HUE16736381A HUE16736381A HUE046631T2 HU E046631 T2 HUE046631 T2 HU E046631T2 HU E16736381 A HUE16736381 A HU E16736381A HU E16736381 A HUE16736381 A HU E16736381A HU E046631 T2 HUE046631 T2 HU E046631T2
Authority
HU
Hungary
Prior art keywords
vegfr
combination therapy
dna vaccine
targeting dna
targeting
Prior art date
Application number
HUE16736381A
Other languages
English (en)
Hungarian (hu)
Inventor
Heinz Lubenau
Original Assignee
Vaximm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm Ag filed Critical Vaximm Ag
Publication of HUE046631T2 publication Critical patent/HUE046631T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HUE16736381A 2015-06-18 2016-06-16 VEGFR-2 targetáló DNS vakcina kombinációs terápiára HUE046631T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15001803 2015-06-18

Publications (1)

Publication Number Publication Date
HUE046631T2 true HUE046631T2 (hu) 2020-03-30

Family

ID=53476620

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16736381A HUE046631T2 (hu) 2015-06-18 2016-06-16 VEGFR-2 targetáló DNS vakcina kombinációs terápiára

Country Status (19)

Country Link
US (2) US10905752B2 (cg-RX-API-DMAC7.html)
EP (2) EP3310379B1 (cg-RX-API-DMAC7.html)
JP (1) JP6947649B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250024816A (cg-RX-API-DMAC7.html)
CN (1) CN107995868B (cg-RX-API-DMAC7.html)
AU (1) AU2016278588B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017027378A2 (cg-RX-API-DMAC7.html)
CA (1) CA2989247C (cg-RX-API-DMAC7.html)
DK (1) DK3310379T3 (cg-RX-API-DMAC7.html)
ES (2) ES2760699T3 (cg-RX-API-DMAC7.html)
HU (1) HUE046631T2 (cg-RX-API-DMAC7.html)
IL (1) IL256076A (cg-RX-API-DMAC7.html)
LT (1) LT3310379T (cg-RX-API-DMAC7.html)
MX (1) MX2017016183A (cg-RX-API-DMAC7.html)
PL (2) PL3310379T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018101722A (cg-RX-API-DMAC7.html)
SI (1) SI3310379T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016202459A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708439B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019112977A (ru) * 2016-11-04 2020-12-04 Факсимм Аг Днк-вакцина, нацеленная на wt1, для комбинированной терапии
SG11201907391SA (en) * 2017-02-17 2019-09-27 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
US11357842B2 (en) 2017-03-17 2022-06-14 Vaximm Ag PD-L1 targeting DNA vaccine for cancer immunotherapy
CA3109430A1 (en) * 2018-09-05 2020-03-12 Vaximm Ag Neoantigen targeting dna vaccine for combination therapy
AU2021208400A1 (en) * 2020-01-13 2022-08-11 Vaximm Ag Salmonella-based DNA vaccines in combination with an antibiotic
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
BR112014015706A2 (pt) * 2011-12-22 2020-10-27 Vaximm Ag método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a
BR112014033046A2 (pt) * 2012-07-05 2017-06-27 Vaximm Ag linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01
PT2897620T (pt) * 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
SG10201710472PA (en) * 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
CN105246496A (zh) * 2013-04-25 2016-01-13 万科斯蒙股份有限公司 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体
BR112016014405A2 (pt) * 2013-12-18 2018-02-20 Vaximm Gmbh cepa mutante atenuada de salmonela
SG11201907391SA (en) * 2017-02-17 2019-09-27 Vaximm Ag Novel vegfr-2 targeting immunotherapy approach
US11357842B2 (en) * 2017-03-17 2022-06-14 Vaximm Ag PD-L1 targeting DNA vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
KR20180037948A (ko) 2018-04-13
EP3310379A1 (en) 2018-04-25
RU2018101722A (ru) 2019-07-18
EP3626262A1 (en) 2020-03-25
CN107995868A (zh) 2018-05-04
MX2017016183A (es) 2018-06-19
RU2018101722A3 (cg-RX-API-DMAC7.html) 2019-12-10
DK3310379T3 (da) 2019-12-16
CA2989247A1 (en) 2016-12-22
ES2760699T3 (es) 2020-05-14
LT3310379T (lt) 2019-12-27
EP3626262B1 (en) 2024-10-23
US20180250345A1 (en) 2018-09-06
PL3310379T3 (pl) 2020-03-31
AU2016278588A1 (en) 2017-12-21
EP3310379B1 (en) 2019-11-06
BR112017027378A2 (pt) 2018-08-28
CA2989247C (en) 2023-10-17
SI3310379T1 (sl) 2020-02-28
ES2994561T3 (en) 2025-01-27
ZA201708439B (en) 2021-05-26
EP3626262C0 (en) 2024-10-23
AU2016278588B2 (en) 2022-03-31
IL256076A (en) 2018-01-31
WO2016202459A1 (en) 2016-12-22
PL3626262T3 (pl) 2025-02-17
US10905752B2 (en) 2021-02-02
JP6947649B2 (ja) 2021-10-13
US20210077605A1 (en) 2021-03-18
HK1252435A1 (en) 2019-05-24
JP2018517419A (ja) 2018-07-05
KR20250024816A (ko) 2025-02-19
CN107995868B (zh) 2021-07-13

Similar Documents

Publication Publication Date Title
EP3364949A4 (en) CANCER VACCINES
ZA201904717B (en) Therapeutic hpv18 vaccines
IL260030B2 (en) Neoepitope therapeutic vaccine against cancer
EP3368656A4 (en) TARGETED CANCER THERAPY
DK3393510T5 (da) Zikavirusvaccine
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
HRP20181895T1 (hr) Terapijska hpv16 cjepiva
IL253719A0 (en) Pharmaceutical compositions for combination therapy
DK3262066T4 (da) Genterapi
MA39483A (fr) Agents thérapeutiques cibles
ZA201808121B (en) Therapeutic hpv vaccine combinations
ZA201708439B (en) Vegfr-2 targeting dna vaccine for combination therapy
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
IL265684A (en) dna vaccine targeting wt1 for combination therapy
DK3329004T3 (da) Terapeutiske oligonukleotider
DK3155004T3 (da) Vaccine til immunkompromitterede værter
GB201506041D0 (en) Avian vaccine
DK3795130T3 (da) Terapiapparat.
DK3277325T3 (da) Kombinationsimmunterapi for cancer
PL3261679T3 (pl) Terapia genowa dla poprawy wzroku
LT3188755T (lt) Vakcina
EP3335072A4 (en) MULTI-CHANNEL OPTOMECHANICAL STIMULATION
HK40009852A (en) Wt1 targeting dna vaccine for combination therapy
TH1601003236A (th) วัคซีนสุกร